Development of biotechnological tools for application in the prevention of leishmaniosis: from the use of DNA vaccines to leishmanisation with a geneticly attenuated strain. (Q3199802): Difference between revisions
Jump to navigation
Jump to search
(Created claim: summary (P836): Over the past twenty years, major efforts have been made to develop Leishmania vaccines based on defined antigens. Some of the characterised immunogenic proteins have been tested as recombinant products in experimental models of leishmaniosis in the mouse. In addition, vaccination strategies have been developed using genetically attenuated parasites to induce effector T lymphocyte responses capable of controlling infection at the inoculation sit...) |
(Changed label, description and/or aliases in en: translated_label) |
||
| label / en | label / en | ||
Development of biotechnological tools for application in the prevention of leishmaniosis: from the use of DNA vaccines to leishmanisation with a geneticly attenuated strain. | |||
Revision as of 23:27, 12 October 2021
Project Q3199802 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Development of biotechnological tools for application in the prevention of leishmaniosis: from the use of DNA vaccines to leishmanisation with a geneticly attenuated strain. |
Project Q3199802 in Spain |
Statements
40,750.0 Euro
0 references
81,500.0 Euro
0 references
50.0 percent
0 references
1 January 2015
0 references
30 March 2019
0 references
UNIVERSIDAD AUTONOMA DE MADRID
0 references
40°25'0.12"N, 3°42'12.89"W
0 references
28079
0 references
Durante los últimos veinte años, se han realizado grandes esfuerzos para desarrollar vacunas contra Leishmania basadas en antígenos definidos. Algunas de las proteínas inmunogénicas caracterizadas se han ensayado como productos recombinantes en modelos experimentales de leishmaniosis en el ratón. Además, se han desarrollado estrategias de vacunación empleando parásitos genéticamente atenuados para inducir respuestas de linfocitos T efectores capaces de controlar la infección en el sitio de inoculación. A pesar de este esfuerzo, no se dispone de vacunas contra las leishmaniosis humanas y las vacunas veterinarias sólo generan una protección parcial. Con el objetivo de aumentar el número de posibles candidatos al desarrollo de vacunas, este Proyecto estudiará las propiedades profilácticas de tres antígenos administrados como vacunas de ADN (alfa-tubulina, S-adenosilmetionina sintetasa y prohibitina), aislados tras una búsqueda inmunoproteómica por ser reconocidos por el suero de pacientes brasileños asintomáticos humanos y caninos. Además, se analizarán las propiedades profilácticas de una cepa atenuada de Leishmana infantum conocida por generar una infección asintomática en un hospedador susceptible (hámster), y que ha demostrado tener capacidades protectoras. Se analizarán las dos estrategias en sendos modelos de leishmaniosis experimental causada por la infección por Leishmania major que reflejan dos formas de evolución diferente de la enfermedad: BALB/c (ratones susceptibles) y C57BL/6 (ratones resistentes). El último objetivo del Proyecto es analizar la capacidad protectora combinada en un ensayo que emplee las vacunas de DNA como primer estímulo y la vacuna atenuada (leishmanizacion) como refuerzo inmunológico. (Spanish)
0 references
Over the past twenty years, major efforts have been made to develop Leishmania vaccines based on defined antigens. Some of the characterised immunogenic proteins have been tested as recombinant products in experimental models of leishmaniosis in the mouse. In addition, vaccination strategies have been developed using genetically attenuated parasites to induce effector T lymphocyte responses capable of controlling infection at the inoculation site. Despite this effort, vaccines against human leishmaniosis are not available and veterinary vaccines only provide partial protection. With the aim of increasing the number of potential candidates for vaccine development, this Project will study the prophylactic properties of three antigens administered as DNA vaccines (alpha-tubulin, S-adenosylmethionine synthetase and prohibitin), isolated after an immunoprotemic search for being recognised by serum of Brazilian asymptomatic human and canine patients. In addition, the prophylactic properties of a attenuated strain of Leishmana infantum known to generate an asymptomatic infection in a susceptible host (hamster) and which have been shown to have protective capabilities will be analysed. The two strategies will be analysed in two models of experimental leishmaniosis caused by Leishmania major infection that reflect two different forms of disease evolution: Balb/c (sensitive mouse) and C57BL/6 (resistant mouse). The last objective of the Project is to analyse the combined protective capacity in a trial that uses DNA vaccines as a first stimulus and the attenuated vaccine (leishmanisation) as an immune booster. (English)
13 October 2021
0 references
Madrid
0 references
Identifiers
PI14_00366
0 references